OOIR: Observatory of International Research

Papers

(The TQCC of mAbs is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	286
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	206
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	109
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	83
Correction	80
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	77
Antibody-mediated degradation of 4R-tau restores mitochondrial membrane polarization in human induced pluripotent stem cell-derived neurons with the MAPT 10+16 mutation	68
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	59
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG ₁ antibodies	56
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody	54
Charge heterogeneity of therapeutic monoclonal antibodies by different cIEF systems: views on the current situation	54
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	52
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	43
Modulation of the high concentration viscosity of IgG ₁ antibodies using clinically validated Fc mutations	40
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody	39
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	36
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches	36
Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice	34
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	34
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	32
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C _H 1-C _λ interfac	32
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	31
Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A	31
Combinatorial Fc modifications for complementary antibody functionality	30
Targeting γc family cytokines with biologics: current status and future prospects	29

Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	29
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 ⁺ T cell interl	28
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	26
In silico prediction of post-translational modifications in therapeutic antibodies	24
Development of T-cell engagers selective for cells co-expressing two antigens	24
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	24
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties	23
In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom	23
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	22
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	22
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	21
A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation	21
Engineering death resistance in CHO cells for improved perfusion culture	21
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	20
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	20
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	20
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy	20
Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics	19
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	18
Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms	17
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	17
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	16
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	16
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers	16
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	16
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	15
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration	15
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	15
Alternative splicing for tuneable expression of protein subunits at desired ratios	14
Correction	14
Understanding the impacts of dual methionine oxidations in complementarity-determining regions on the structure of monoclonal antibodies	14
Reduction of monoclonal antibody viscosity using interpretable machine learning	14
Prediction of long-term stability of high-concentration formulations to support rapid development of antibodies against SARS-CoV-2	14
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring	13
Heavy chain-only antibodies with a stabilized human VH in transgenic chickens for therapeutic antibody discovery	13
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	13
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate	13
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies	13
Expanding the structural resolution of glycosylation microheterogeneity in therapeutic proteins by salt-free hydrophilic interaction liquid chromatography tandem mass spectrometry	13
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1	12
Correction	12
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy	12
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	12
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	12
Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen	12
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches	11
Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study	11
An antibody developability triaging pipeline exploiting protein language models	11
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2	11
Predicting purification process fit of monoclonal antibodies using machine learning	11

PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning	11
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT	11
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics	10
Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development	10
Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies	10
Investigating protein–excipient interactions of a multivalent V _HH therapeutic protein using NMR spectroscopy	10
Correction	10
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method	10
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	10